Current treatment strategies in early stage hodgkin’s disease

Current Treatment Options in Oncology

Volumn 4, Issue 4, 2003, Pages 297-305

  Josting, Andreas ^a   Diehl, Volker ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b NONE

Author keywords

Clin Oncol; Combine Modality Therapy; Combine Modality Treatment; German Hodgkin Study Group; Splenic Irradiation

Indexed keywords

ARTICLE; HODGKIN DISEASE; HUMAN; MULTIMODALITY CANCER THERAPY;

COMBINED MODALITY THERAPY; HODGKIN DISEASE; HUMANS;

EID: 0642304824     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-003-0005-z     Document Type: Article

References (34)

1. Carde P, Burger JM, Henry-Amar M: Clinical stages I and II Hodgkin’s disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol 1988, 6:239–248.
2. Josting A, Wolf J, Diehl V: Hodgkin’s disease: prognostic factors and treatment strategies. Curr Opin Oncol 2000, 12, 403–411. DOI: 10.1097/00001622-200009000-00004
3. Jones E, Mauch P: Limited radiation therapy for selected patients with stages IA and IIA Hodgkin’s disease. Semin Radiat Oncol 1996, 6:162–171. DOI: 10.1016/S1053-4296(96)80013-0
4. Biti G, Cimino G, Cartoni C, et al.: Extended-field radiotherapy is superior to MOPP chemotherapy for the treatment of pathologic stage I-IIA Hodgkin’s disease: eight-year update of an Italian prospective randomized study. J Clin Oncol 1992, 10:378–382.
5. Specht L, Horwich A, Ashley S: Salvage of relapse of patients with Hodgkin’s disease in clinical stages I or II who were staged with laparotomy and initially treated with radiotherapy alone: a report from the International Database on Hodgkin’s Disease. Int J Radiat Oncol Biol Phys 1994, 30:805–811.
6. Horwich A, Specht L, Ashley S: Survival analysis of patients with clinical stages I or II Hodgkin’s disease who have relapsed after initial treatment with radiotherapy alone. Eur J Cancer 1997, 33:848–853. DOI: 10.1016/S0959-8049(96)00518-7
7. Tucker M, Coleman C, Cox R: Risk of second cancers after treatment for Hodgkin’s disease. N Engl J Med 1988, 318:76–81. DOI: 10.1056/NEJM198801143180203
8. Henry-Amar M: Second cancer after the treatment for Hodgkin’s disease: a report from the International Database on Hodgkin’s Disease. Ann Oncol 1992, 3(Suppl 4):117–128.
9. Aisenberg A, Finkelstein D, Doppke K, et al.: High risk of breast carcinoma after irradiation of young women with Hodgkin’s disease. Cancer 1997, 79:1203–1210. DOI: 10.1002/(SICI)1097-0142(19970315)79:6<1203::AID-CNCR20>3.0.CO;2-2
10. Kaplan HS: Role of intensive radiotherapy in the management of Hodgkin’s disease. Cancer 1966, 19:356. DOI: 10.1002/1097-0142(196603)19:3<356::AID-CNCR2820190308>3.0.CO;2-B
11. Vijayakumar S, Myrianthopoulos L: An updated doseresponse analysis in Hodgkin’s disease. Radiother Oncol 1992, 24:1–13. DOI: 10.1016/0167-8140(92)90347-W
12. Duhmke E, Franklin J, Pfreundschuh M, et al.: Low-dose radiation is sufficient for the noninvolved extendedfield treatment in favorable early-stage Hodgkin’s disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 2001, 19:2905–2914. A prospective randomized phase III trial defining the dose in EF radiotherapy. This study shows that subclinical involvement of HD is treated sufficiently with 30 Gy radiotherapy alone.
13. Sieber M, Franklin J, Tesch H, et al.: Two cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin’s disease: results of the German Hodgkin’s Lymphoma Study Group (GHSG) Trial HD7 [abstract]. Blood 2002, 100:341. DOI: 10.1182/blood.V100.1.341
14. Press OW, LeBlanc M, Lichter AS, et al.: Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin’s disease. J Clin Oncol 2001, 19:4238–4244. A prospective randomized phase III study comparing three cycles of doxorubicin and vinblastine plus subtotal nodal and splenic irradiation with subtotal nodal and splenic irradiation alone in early stage favorable HD. The FFP rates at 3 years were 94% and 81%, respectively, showing a benefit for the combined modality arm.
15. Carde P, Noordijk E, Hagenbeek A: Superiority of EBVP chemotherapy in combination with involved field irradiation over subtotal nodal irradiation in favorable clinical stage I-II Hodgkin’s disease: The EORTCGPMC H7F randomized trial. Proc Amer Soc Clin Oncol 1997, 16:13.
16. Hagenbeek A, Eghbali H, Fermé C, et al.: Three cycles of MOPP/ABV hybrid and involved-field irradiation is more effective than subtotal nodal irradiation in favorable supradiaphragmatic clinical stages I-II Hodgkin’s disease: preliminary results of the EORTCGELA H8-F randomized trial in 543 patients [abstract]. Blood 2000, 96:575.
17. Horning S, Hoppe R, Hancock S: Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin’s disease. J Clin Oncol 1988, 6:1822–1831.
18. Horning S, Hoppe R, Mason J, et al.: Stanford-Kaiser Permanent G1 study for clinical stage I to IIA Hodgkin’s disease: subtotal lymphoid irradiation versus vinblastine, methotrexate, and bleomycin chemotherapy and regional irradiation. J Clin Oncol 1997, 15:1736–1744.
19. Bates N, Williams M, Bessell E, et al.: Efficacy and toxicity of vinblastine, bleomycin, and methotrexate with involved-field radiotherapy in clinical stage IA and IIA Hodgkin’s disease: a British National Lymphoma Investigation pilot study. J Clin Oncol 1994, 12:288–296.
20. Santoro A, Viviani S, Zucali R: Comparative results and toxicity of MOPP versus ABVD combined with radiotherapy (RT) in PS IIB, III (A,B) Hodgkin’s disease (HD). Paper presented at the Annual Meeting of the American Society of Clinical Oncology. San Diego, CA; 1983.
21. Cosset J, Ferme C, Noordijk E: Combined modality therapy for poor prognosis stages I and II Hodgkin’s disease. Semin Radiat Oncol 1996, 6:185–195. DOI: 10.1016/S1053-4296(96)80015-4
22. Noordijk E, Carde P, Hagenbeek A: Combination of radiotherapy and chemotherapy is advisable in all patients with clinical stage I-II Hodgkin’s disease. Sixyear results of the EORTC-GPMC controlled clinical trials H7-VF, H7-F and H7-U. Int J Radiat Oncol Biol Phys 1997, 39:173. DOI: 10.1016/S0360-3016(97)80635-9
23. Pavlovsky S, Schvartzman E, Lastiri F, et al.: Randomized trial of CVPP for three versus six cycles in favorable prognosis and CVPP versus AOPE plus radiotherapy in intermediate prognosis untreated Hodgkin’s disease. J Clin Oncol 1997, 15:2652–2658.
24. Hagemeister F, Purugganan R, Fuller L, et al.: Treatment of early stages of Hodgkin’s disease with novantrone, vincristine, vinblastine, prednisone, and radiotherapy. Semin Hematol 1994, 31:36–43.
25. Andre M, Brice P, Cazals D, et al.: Results of three courses of adriamycin, bleomycin, vindesine, and dacarbazine with subtotal nodal irradiation in 189 patients with nodal Hodgkin’s disease (stage I, II and IIIA). Hematol Cell Ther 1997, 39:59–65. DOI: 10.1007/s00282-997-0059-7
26. Horning SJ, Hoppe RT, Breslin S, et al.: Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol 2002, 20:630–637. DOI: 10.1200/JCO.20.3.630
27. Horning S, Rosenberg S, Hoppe R: Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin’s disease: an update. Ann Oncol 1996, 7(Suppl 4):105–108.
28. Loeffler M, Diehl V, Pfreundschuh M, et al.: Doseresponse relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin’s disease. J Clin Oncol 1997, 15:2275–2287.
29. Zittoun R, Audebert A, Hoerni B, et al.: Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin’s disease. J Clin Oncol 1985, 3:207–214.
30. Engert A, Petra Schiller P, Josting A, et al.: Involved field (IF) radiotherapy is equally effective and less toxic as compared with extended field (EF) radiotherapy after four cycles of chemotherapy in patients with earlystage unfavourable Hodgkin’s disease: results of the HD8 trial of the German Hodgkin Study Group (GHSG). J Clin Oncol, 2003, in press. This prospectively randomized study by the GHSG, comparing 30 Gy radiotherapy in the EF or IF technique, defines a new standard of treatment for patients with early unfavorable stage HD (ie, four cycles of effective chemotherapy, followed by IF radiotherapy).
31. Ferme C, Eghbali H, Hagenbeek A, et al.: MOPP/ABV hybrid and irradiation in unfavorable supradiaphragmatic clinical stages I-II Hodgkin’s disease: comparison of three treatment modalities. Preliminary results of the EORTC-GELA H8-U randomized trial in 995 patients [abstract]. Blood 2000, 96:576.
32. Brusamolino E, Lazzarino M, Orlandi E, et al.: Earlystage Hodgkin’s disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy. Ann Oncol 1994, 5(Suppl 2):101–106.
33. Colonna P, Jais J, Desablens B, et al.: Mediastinal tumor size and response to chemotherapy are the only prognostic factors in supradiaphragmatic Hodgkin’s disease treated by ABVD plus radiotherapy: 10-year results of the Paris-Ouest-France 81/12 trial, including 262 patients. J Clin Oncol 1996, 14:1928–1935.
34. Pavlovsky S, Maschio M, Santarelli M, et al.: Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin’s disease. J Natl Cancer Inst 1988, 80:1466–1473. DOI: 10.1093/jnci/80.18.1466